Pharmacological treatment of obsessive-compulsive disorder

Current Topics in Behavioral Neurosciences

Volumn 2, Issue , 2010, Pages 527-543

  Simpson, Helen Blair ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

CBT; Medications; OCD; Serotonin reuptake inhibitors; Treatment guidelines

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; CYCLOSERINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; RILUZOLE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

AGITATION; ANOREXIA; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EJACULATION DISORDER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; LETHARGY; LIBIDO DISORDER; LOW DRUG DOSE; MYOCLONUS; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORGASM DISORDER; PARESTHESIA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RELAPSE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SUICIDE ATTEMPT; SWEAT GLAND DISEASE; TREATMENT DURATION; VIVID DREAM; VOMITING; WITHDRAWAL SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952260712     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2009_12     Document Type: Review

References (77)

1. Aboujaoude E, Barry JJ, Gamel N (2009) Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29:51-55
2. Ackerman DL, Greenland S (2002) Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 22:309-317
3. Albert U, Aguglia E, Maina G, Bogetto F (2002) Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 63:1004-1009
4. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric Association (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164(Suppl):1-56
5. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622-632
6. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S (2004) Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 65:565-568
7. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5:5
8. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66:49-51
9. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424-428
10. Davis M, Myers KM, Chhatwal J, Ressler KJ (2006) Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx 3:82-96
11. Dell'osso B, Mundo E, Marazziti D, Altamura AC (2008) Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol 22:210-213
12. Denys D, de Geus F, van Megen HJ, Westenberg HG (2004a) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048
13. Denys D, van der Wee N, van Megen HJ, Westenberg HG (2003) A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 23:568-575
14. Denys D, van Megen HJ, van der Wee N, Westenberg HG (2004b) A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65:37-43
15. Eddy KT, Dutra L, Bradley R, Westen D (2004) A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24:1011-1030
16. El Mansari M, Blier P (2006) Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:362-373
17. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X (2005) Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162:151-161
18. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ (1994) Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55:301-305
19. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ (2007) Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 164:1044-1049
20. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K et al (1995a) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52:289-295
21. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC (1995b) Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 52:53-60
22. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339
23. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW (2006) Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63:298-304
24. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB (2003) Acute and longterm treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64:1113-1121
25. Huppert JD, Simpson HB, Nissenson KJ, Liebowitz MR, Foa EB (2009) Quality of life and functional impairment in obsessive-compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls. Depress Anxiety 26(1):39-45
26. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL (1983) D-amphetamine in obsessivecompulsive disorder. Psychopharmacology (Berl) 80:231-235
27. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL (1985) Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 20:1174-1188
28. Jenike MA, Baer L, Greist JH (1990) Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 10:122-124
29. Joffe RT, Swinson RP (1987) Methylphenidate in primary obsessive-compulsive disorder. J Clin Psychopharmacol 7:420-422
30. Joffe RT, Swinson RP, Levitt AJ (1991) Acute psychostimulant challenge in primary obsessivecompulsive disorder. J Clin Psychopharmacol 11:237-241
31. Kampman M, Keijsers G, Hoogduin C, Verbraak M (2002) Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatrica Scandinavica 106:314-319
32. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602
33. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M (2005a) Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 66:353-359
34. Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN (2005b) Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 66:515-520
35. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D (2002) Efficacy of sertraline in the longterm treatment of obsessive-compulsive disorder. Am J Psychiatry 159:88-95
36. Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA (1996) Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 16:121-129
37. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB (2007) D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 62:835-838
38. Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V (2006) N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 184:254-256
39. Lopez-Ibor JJ Jr, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, Hernandez M, Gomez-Perez JC (1996) Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 6:111-118
40. Maina G, Albert U, Ziero S, Bogetto F (2003) Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol 18:23-28
41. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, WeissmanEM, Wirshing DA, Hall CS, Pogach L, Pi-SunyerX, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334-1349
42. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH (1995) Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152:1812-1814
43. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebocontrolled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessivecompulsive disorder. Arch Gen Psychiatry 57:794-801
44. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebocontrolled study in patients with and without tics. Arch Gen Psychiatry 51:302-308
45. Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM (2001) Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessivecompulsive disorder. Int Clin Psychopharmacol 16:75-86
46. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 3:143-152
47. Mundo E, Maina G, Uslenghi C (2000) Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 15:69-76
48. Murray C, Lopez A (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge, MA
49. Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C (2006) High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 67:15-22
50. Pasquini M, Biondi M (2006) Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:1173-1175
51. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL (1988) Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 145:1521-1525
52. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL (1990) Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 47:926-932
53. Pigott TA, Seay SM (1999) A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106
54. Pittenger C, Krystal JH, Coric V (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3:69-81
55. Poyurovsky M, Weizman R, Weizman A, Koran L (2005) Memantine for treatment-resistant OCD. Am J Psychiatry 162:2191-2192
56. Rasmussen SA, Eisen JL (1994) The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 55(Suppl):5-10; discussion 11-14
57. Ressler KJ, Mayberg HS (2007) Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 10:1116-1124
58. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136-1144
59. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, Regier DA (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949-958
60. Romano S, Goodman W, Tamura R, Gonzales J (2001) Long-term treatment of obsessivecompulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 21:46-52
61. Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2008) The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry [Epub ahead of print]
62. Shapira NA, Keck PE Jr, Goldsmith TD, McConville BJ, Eis M, McElroy SL (1997) Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 6:170-173
63. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK (2004) A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 55:553-555
64. Simon GE, Savarino J, Operskalski B, Wang PS (2006) Suicide risk during antidepressant treatment. Am J Psychiatry 163:41-47
65. Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E (2008) A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry 165:621-630
66. Skoog G, Skoog I (1999) A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 56:121-127
67. Stahl SM (2008) Stahl's essential psychopharmacology. Cambridge University Press, New York
68. Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK (2008) Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 25:172-174
69. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK (2007) D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 22:230-237
70. Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C (1996) Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry 57:257-264
71. Tamam L, Ozpoyraz N (2002) Comorbidity of anxiety disorder among patients with Bipolar I disorder in remission. Psychopathology 35:203-209
72. Tenneij NH, van Megen HJ, Denys DA, Westenberg HG (2005) Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry 66:1169-1175
73. Van Ameringen M, Mancini C, Patterson B, Bennett M (2006) Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 23:1-5
74. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL (2008) Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 165:335-341; quiz 409
75. Yaryura-Tobias JA, Neziroglu FA (1996) Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry 53:653-654
76. Zajecka J, Tracy KA, Mitchell S (1997) Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58:291-297
77. Zohar J, Judge R (1996) Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 169:468-474